The company’s first patent of 2020 provides protections for its Central Line Simulator, a procedural training device used by specialized physicians to practice skills related to the insertion of central venous access devices.
TAMPA, Fla. – SynDaver, an advanced bio-technology company specializing in the creation of synthetic human and animal simulators for education, medical testing and training, announced today, the U.S. Patent and Trademark Office granted U.S. Patent 10,553,131, which covers the intellectual property of the company’s Central Line Simulation and Training Device.
James JudgeUSPTO grants patent to SynDaver for its central line simulation technology, expanding the company’s patent portfolio to 16
SynDaver’s 14th patent has been issued to cover the intellectual property for its cricothyroidotomy and nasogastric intubation simulation technology, which enables students in the medical field to gain hands-on training performing these challenging airway procedures.
James JudgeSynDaver receives patent for its Cricothyroidotomy and Nasogastric tube medical simulation trainer
SynDaver Labs’ tenth U.S. Patent (No 8,801,438) was issued today. This patent covers anatomic models that comprise components that simulate human or non-human animal components. The models may be used for development, experimentation, or training in the field of orthopedic surgical devices, and/or implant devices. The models may also be used for training of students in the medical field for procedures performed in practice, such as for example drawing blood from a patient, or placing a central line in a carotid artery of a patient. In exemplary embodiments, the models comprise structures such as cartilage, tendons, ligaments, organs, luminal structures, and muscles that are made of hydrogel materials.
SynDaver Labs’ ninth U.S. Patent (No 8,512,044) was allowed today. The patent covers the design and manufacturing of synthetic human anatomy models which possessing a level of correlation to dielectric properties of human or nonhuman animal tissues that allows them to be substituted for either a live animal, an animal cadaver, or a human cadaver in the testing of medical devices.
SynDaver™ Labs’ seventh U.S. Patent (No 8,137,110) was issued today. The patent covers the design and manufacturing of synthetic human tissues which mimic the dielectric properties of a relevant living human tissue.
SynDaver™ Labs’ sixth U.S. patent (No 7,993,140) issued today. The patent covers the design of synthetic human body parts and the formulation of synthetic human tissues for medical device testing, surgical simulation, and clinical task training.
SynDaver™ Labs’ fourth (No 7,677,897) and fifth (No 7,699,615) U.S. Patents issued recently. These patents cover synthetic human body parts involving joints and methods involved in testing medical devices in soft tissue models. These patents add to our expanding portfolio of U.S. and international intellectual property. Our company and affiliates currently have more than 20 additional U.S. and international patent applications in process.
SynDaver™ Labs’ third U.S. patent (No 7,507,092) issued today. The patent covers synthetic human body parts with living cells. This technology will expand the use of SynDaver™ Labs’ technology beyond medical device testing to pharmaceuticals, cosmetics, and consumer products.
SynDaver™ Labs’ second U.S. patent (No 7,427,199) issued today. The patent covers the design of synthetic human body parts and the formulation of synthetic human tissues for medical device testing, surgical simulation, and clinical task training.